Page contentsPage contents Key facts Decision Key facts Active substance senaparib Therapeutic area Neoplasms benign, malignant and unspecified (incl cysts and polyps) Decision number EMA/PE/0000238615 PIP number EMA/PE/0000238615 Pharmaceutical form(s) All pharmaceutical forms Condition(s) / indication(s) Treatment of peritoneal cancer Route(s) of administration All routes of administration Contact for public enquiries Shanghai Impact Therapeutics Co. Ltd. Tel. +86 21 68411121 E-mail: regulatoryaffairs@impacttherapeutics.com Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 15/04/2025 Compliance check done No Decision EMA/PE/0000238615: EMA decision of 15 April 2025 on the granting of a product specific waiver for senaparibAdopted Reference Number: EMADOC-1700519818-2039233 English (EN) (219.18 KB - PDF)First published: 30/06/2026 View Share this page